U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07461454) titled 'YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer' on March 04.
Brief Summary: The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.
Study Start Date: March 10
Study Type: INTERVENTIONAL
Condition:
Locally Advanced or Metastatic Breast ...